Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $33.59 Average Price Target from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $33.5909.

Several analysts recently weighed in on ROIV shares. Guggenheim lifted their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target for the company.

Insider Activity

In other news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at $53,489,169.08. This trade represents a 11.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the sale, the director owned 13,701,546 shares in the company, valued at $473,388,414.30. This represents a 5.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 2,359,225 shares of company stock worth $77,401,516. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. SBI Securities Co. Ltd. grew its position in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in Roivant Sciences in the fourth quarter worth about $47,000. Parallel Advisors LLC increased its stake in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after purchasing an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after purchasing an additional 2,665 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $35.13 on Monday. The firm has a 50-day moving average of $30.24 and a 200-day moving average of $27.30. The firm has a market cap of $25.27 billion, a P/E ratio of -58.55 and a beta of 1.11. Roivant Sciences has a 1-year low of $10.70 and a 1-year high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period last year, the firm earned ($0.29) earnings per share. Research analysts forecast that Roivant Sciences will post -1.83 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.